Comparison of scPharmaceuticals Inc. (SCPH) and BioXcel Therapeutics Inc. (NASDAQ:BTAI)

This is a contrast between scPharmaceuticals Inc. (NASDAQ:SCPH) and BioXcel Therapeutics Inc. (NASDAQ:BTAI) based on their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
scPharmaceuticals Inc. N/A 0.00 29.43M -1.59 0.00
BioXcel Therapeutics Inc. N/A 0.00 22.19M -1.33 0.00

Table 1 highlights scPharmaceuticals Inc. and BioXcel Therapeutics Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of scPharmaceuticals Inc. and BioXcel Therapeutics Inc.

Net Margins Return on Equity Return on Assets
scPharmaceuticals Inc. 0.00% -36.7% -30.6%
BioXcel Therapeutics Inc. 0.00% -53.2% -48.5%

Liquidity

The current Quick Ratio of scPharmaceuticals Inc. is 8.5 while its Current Ratio is 8.5. Meanwhile, BioXcel Therapeutics Inc. has a Current Ratio of 5.6 while its Quick Ratio is 5.6. scPharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than BioXcel Therapeutics Inc.

Institutional & Insider Ownership

The shares of both scPharmaceuticals Inc. and BioXcel Therapeutics Inc. are owned by institutional investors at 77.4% and 20.9% respectively. 0.1% are scPharmaceuticals Inc.’s share held by insiders. Competitively, BioXcel Therapeutics Inc. has 1.1% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
scPharmaceuticals Inc. -5.12% 41.94% 6.34% -25.11% -75.38% -6.38%
BioXcel Therapeutics Inc. -8.91% 5.4% 4.27% 82.03% 13.05% 178.24%

For the past year scPharmaceuticals Inc. has -6.38% weaker performance while BioXcel Therapeutics Inc. has 178.24% stronger performance.

scPharmaceuticals Inc., biopharmaceutical company, engages in the development and commercialization of transformative pharmaceutical products. The company's under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts.

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is headquartered in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.